AbCellera Biologics Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- AbCellera Biologics Inc. (ABCL) is a biotechnology company that discovers and develops antibody-based therapeutics using proprietary AI-powered platforms for target discovery, antibody discovery, and optimization. The company offers integrated services including de novo antibody discovery from immune cells; computational protein design and engineering; and GPCR and ion channel screening technologies, with key partnerships supporting programs in oncology, metabolic and endocrine conditions, and autoimmune diseases. AbCellera operates primarily in North America and Europe, serving pharmaceutical and biotechnology partners; it was founded in 2012 and is headquartered in Vancouver, Canada. Core products and services encompass the AbCellera Engine platform, which combines microfluidics, deep learning AI, and single-cell analysis for rapid antibody isolation; proprietary FC Sort and FC Nano technologies for high-throughput functional screening; and end-to-end development support from discovery to preclinical candidates, including bispecific antibodies and antibody-drug conjugates under brands like those partnered with Eli Lilly and Novartis. The company targets large-molecule therapeutics across immunology, neurodegeneration, and infectious diseases, with a pipeline featuring wholly-owned assets such as ABCL635 for metabolic disorders and partnered programs advancing in Phase 1 trials. In the last 1-2 years, AbCellera expanded its strategic alliances, including a major multi-target collaboration with AbbVie in 2024 for immunology and neuroscience antibodies; launched new proprietary programs like ABCL575 targeting T-cell mediated autoimmune diseases; and completed a $225 million strategic financing round in late 2024 led by existing partners to fuel internal pipeline advancement and AI platform enhancements. The company also advanced clinical milestones, with partner Eli Lilly dosing first patients in Phase 1 for bebtelovimab follow-ons and initiating new GPCR-focused discovery deals. These developments underscore AbCellera's shift toward balancing partner-funded discovery with owned clinical assets amid biotech market dynamics.
Has ABCELLERA BIOLG (ABCL) Outpaced Other Medical Stocks This Year?
After Golden Cross, AbCellera Biologics Inc. (ABCL)'s Technical Outlook is Bright
Wall Street Analysts Believe ABCELLERA BIOLG (ABCL) Could Rally 97.28%: Here's is How to Trade
7 Healthcare AI Stocks Under $50 With Huge Upside Potential
Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year?
AbCellera Biologics Inc. (ABCL) Presents at Bank of America Global Healthcare Conference 2026 Transcript
AbCellera Biologics Inc. (ABCL) Q1 2026 Earnings Call Transcript
AbCellera Biologics Q1 Earnings Call Highlights
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Beats Revenue Estimates
AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635
AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call
AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026
AbCellera Biologics Inc. (ABCL) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript
AbCellera Biologics Inc. (ABCL) Presents at TD Cowen 46th Annual Health Care Conference Transcript
AbCellera Biologics Pivots to Pipeline as ABCL635 Phase II Hot Flash Data Nears, Exec Says
What Sparked AbCellera Biologics To Soar Over 9% After Hours
AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Tops Revenue Estimates
AbCellera Biologics Inc. (ABCL) Q4 2025 Earnings Call Transcript
AbCellera Reports Full Year 2025 Business Results
AbCellera Biologics Inc. (NASDAQ:ABCL) Given Average Recommendation of “Hold” by Brokerages